Earnings Results
VistaGen Therapeutics (NASDAQ:VTGN) reported quarterly earnings results on August 14, 2026 that exceeded analyst expectations.
The Healthcare company reported earnings per share of $-0.30, beating the consensus estimate of $-0.35 by $0.05 per share. Revenue came in at $1.5M, beating the estimate of $166.7K.
Company Overview
VistaGen Therapeutics's stock moved following the earnings release. The stock currently trades at $0.27 with a market capitalization of $129.3M.
VistaGen Therapeutics's earnings outperformance reflects execution that exceeded Wall Street's expectations. Earnings beats can lead to upward estimate revisions from analysts, which often correlate with sustained stock price appreciation over the following weeks as models are updated.
The 14% beat relative to consensus estimates is a notable deviation. Earnings surprises of this magnitude often trigger analyst revisions and can influence institutional positioning in the weeks following the report.
Earnings reports are most useful when viewed as part of a trend rather than in isolation. Investors tracking VistaGen Therapeutics should compare this quarter's results against both year-over-year figures and sequential performance to identify whether the business is accelerating, stabilizing, or decelerating. The earnings calendar on Smart Investors Daily tracks upcoming report dates across all publicly traded companies.
VistaGen Therapeutics Earnings History
| Quarter | EPS Actual | EPS Est. | Surprise |
| Q1 (Aug 2026) | $-0.30 | $-0.35 | +14.3% |
| Q4 (Jun 2026) | $-0.37 | $-0.30 | -23.3% |
| Q3 (Feb 2026) | $-0.45 | $-0.39 | -15.4% |
Related Tools: Earnings Calendar | View VTGN Stock Page
Frequently Asked Questions
When does VistaGen Therapeutics report earnings?
Check the latest earnings dates on our VTGN earnings page or the Earnings Calendar.
Did VTGN beat earnings estimates?
See the full Q1 results including EPS actual vs estimate on our VTGN earnings page.